The COVID vaccines were failed day 1 because 1) Mortal antigenic sin's (original antigen sin) sub-optimal prejudiced initial prime & 2) no immunological stimulation of the mucosal barrier/lining

I will focus on # 2 here and write more on # 1 later

It is as simple as this: for viral transmission to be constrained and stopped in the mucosal lining/barrier, in your nasopharyngeal passage (nostrils etc.) where the virus initially lands, then the mucosae must be stimulated with some form of intranasal vaccine…e.g. nasal vaccine. Not an intramuscular deltoid vaccine. Or the vaccinal antibodies must reach the mucosal layer. The distance however, is too great for the vaccinal antibodies to get to the mucosae. And because none of the above happens with these vaccines, the vaccine cannot work.

This is why it has failed and will fail and no ‘OMI’ spike-specific vaccine must be built. Moreover, because of the non-sterilizing nature of the vaccine, then it cannot stop transmission. Thus with MASS vaccination in the midst of a pandemic with circulating pathogen, using a vaccine that does not sterilize the virus, with simultaneous viral infectious pressure and mounting sub-optimal vaccinal immune pressure, then this is ripe for natural selection to ‘select’ the ‘fittest’ variant, the most infectious, most likely most non-lethal variant as the new dominant. From among variants that could overcome the sub-optimal ‘immature’ and ‘undeveloped’ vaccinal immunity’.

I think I am writing kind of the same thing several times, but it is not to be repetitive, really I am trying to articulate what giants like GVB ascribe to and what based on the knowledge I have, is likely the situation at hand.

Lapointe et al. writes “Several effective SARS-CoV-2 vaccines are currently in use, but in the light of waning immunity and the emergence of novel variants, effective boost modalities are needed in order to maintain or even increase immunity. Here we report that intranasal vaccinations with adenovirus 5 and 19a vectored vaccines following a systemic DNA or mRNA priming result in strong systemic and mucosal immunity in mice. In contrast to two intramuscular injections with an mRNA vaccine, the mucosal boost with adenoviral vectors induced high levels of IgA and tissue-resident memory T cells in the respiratory tract. Mucosal neutralization of virus variants of concern was also enhanced by the intranasal boosts. Importantly, priming with mRNA provoked a more comprehensive T cell response consisting of circulating and tissue-resident memory T cells after the boost, while a DNA priming induced mostly mucosal T cells. Concomitantly, the intranasal boost strategies provided protection against symptomatic disease. Therefore, a mucosal booster immunization after mRNA priming is a promising approach to establish mucosal immunity in addition to systemic responses.”